Curanex Pharmaceuticals regained Nasdaq Listing Rule 5550 compliance after its common stock maintained a closing bid price of at least $1.00 per share. The determination closes the listing matter, meaning Curanex satisfied the minimum-bid-price requirement described in the company update and remains compliant with that Nasdaq rule.
Key Highlights
- Curanex completed a Reverse Stock Split on August 20, 2026.
- Nasdaq Staff notified Curanex of the compliance determination on September 3, 2026.
- Curanex’s update was signed by Chief Executive Officer Jun Liu on September 4, 2026.
Curanex Pharmaceuticals Inc. (NASDAQ: CURX) regained compliance with Nasdaq’s minimum-bid-price requirement after its common stock maintained a closing bid of at least $1.00 per share. Nasdaq Staff determined that the listing issue was resolved, and the matter is now closed.
Reverse Stock Split Preceded Nasdaq Resolution
Curanex carried out a reverse stock split of its outstanding common stock on August 20, 2026, with the stated purpose of restoring compliance with Nasdaq Listing Rule 5550. The action followed a November 5, 2025 notification that the company had fallen below Nasdaq’s minimum bid-price standard over the required business-day period. Nasdaq Staff delivered its compliance determination on September 3, 2026. The company’s update identified the closing bid price as the measure used to assess compliance.
Listing Matter Closed
The Nasdaq determination returned Curanex to compliance with Listing Rule 5550. The company said the matter is closed following the finding that its common stock had met the $1.00-per-share threshold. Chief Executive Officer Jun Liu signed the update for Curanex Pharmaceuticals on September 4, 2026. The signature was made under the requirements of the Securities Exchange Act of 1934.
FAQs
Q: Why did Curanex Pharmaceuticals regain Nasdaq compliance?
A: Curanex Pharmaceuticals regained Nasdaq compliance because its common stock maintained a closing bid price of at least $1.00 per share. Nasdaq Staff determined that the Listing Rule 5550 issue was resolved and closed the matter.
Q: What action did Curanex take before regaining compliance?
A: Curanex completed a reverse stock split on August 20, 2026. The company stated that the action was intended to restore compliance with Nasdaq Listing Rule 5550.
Q: When did Nasdaq confirm Curanex’s compliance?
A: Nasdaq Staff notified Curanex of the compliance determination on September 3, 2026. The decision followed the company’s common stock meeting the minimum bid-price requirement.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.